10-Q: Achieve Life Sciences Q3 2025: NDA Accepted, Vaping Priority

Achieve Life Sciences reports Q3 2025 results, highlighting FDA acceptance of its cytisinicline NDA for smoking cessation and a national priority voucher for vaping cessation, amidst ongoing financing needs and a supplier dispute.

Summary

• Net loss for the nine months ended September 30, 2025, was $39.986 million, compared to $27.467 million for the same period in 2024.
• Cash, cash equivalents, and marketable securities totaled $48.1 million as of September 30, 2025, up from $34.4 million at December 31, 2024.
• Working capital was $40.3 million as of September 30, 2025, compared to $29.8 million at December 31, 2024.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $31.5 million, an increase from $20.6 million in the prior year period.
• The FDA accepted the New Drug Application (NDA) for cytisinicline for smoking cessation, with a Prescription Drug User Fee Act (PDUFA) target action date of June 20, 2026.
• Cytisinicline received Breakthrough Therapy designation and a Commissioners National Priority Voucher (CNPV) for nicotine e-cigarette (vaping) cessation.
• The ORCA-OL open-label safety trial for cytisinicline was completed in September 2025, with safety data submitted to the FDA.
• A dispute exists with Sopharma regarding the engagement of third-party manufacturers for cytisinicline, which Sopharma alleges is a breach of agreement.
• The company drew down an additional $5.0 million from the New Convertible Term Loan in October 2025.
• The Jefferies Open Market Sale Agreement was terminated on November 6, 2025, with no sales made under it during the reported period.
• Entered into two development agreements with Adare Pharma Solutions, a related party, expecting to incur approximately $2.0 million in expenses.

Sentiment

Score: 4

Explanation: While significant regulatory milestones (NDA acceptance, Breakthrough Therapy, CNPV) are positive, the substantial increase in net loss and cash burn, coupled with the explicit 'going concern' warning and ongoing need for significant capital, indicate a challenging financial position. The Sopharma dispute adds further uncertainty.

Positives

• The FDA accepted the NDA for cytisinicline for smoking cessation, assigning a PDUFA target action date of June 20, 2026.
• Cytisinicline received Breakthrough Therapy designation for nicotine e-cigarette (vaping) cessation, which expedites development and review.
• The company was awarded a Commissioners National Priority Voucher (CNPV) for vaping cessation, providing enhanced communication with FDA and expedited review (1-2 months post-filing).
• Completion of the ORCA-OL open-label safety trial in September 2025, with positive safety review by the Data Safety Monitoring Committee (DMSC) in November 2025, finding no concerns with drug safety.
• The FDA agreed on a single Phase 3 study design for a future supplemental NDA (sNDA) submission for vaping cessation, leveraging existing ORCA-V1 and ORCA-OL safety data.
• Cash, cash equivalents, and marketable securities increased to $48.1 million as of September 30, 2025, from $34.4 million at December 31, 2024.
• The company maintained a positive working capital balance of $40.3 million as of September 30, 2025.
• Secured an additional $5.0 million tranche from the New Convertible Term Loan in October 2025, following NDA acceptance.
• Management believes cytisinicline is differentiated by its efficacy, well-tolerated safety profile, and potential for shorter therapy duration compared to existing treatments.
• The company is planning to commence commercial sales in the U.S. in the second half of 2026, utilizing AI tools to enhance marketing and sales efforts.

Negatives

• Incurred a net loss of $39.986 million for the nine months ended September 30, 2025, an increase from $27.467 million for the same period in 2024.
• Net cash used in operating activities increased to $31.5 million for the nine months ended September 30, 2025, from $20.6 million in the prior year period.
• The accumulated deficit reached $245.6 million as of September 30, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern, dependent on obtaining additional financing.
• Current resources are insufficient to fund planned operations for the next 12 months.
• Sopharma has alleged that the company's engagement of third-party manufacturers is a breach of their agreement, which could lead to litigation, additional costs, or delays.
• General and administrative expenses increased significantly due to commercial launch preparation and employee costs.
• Interest income decreased due to lower average cash balances and lower interest rates.
• The company has incurred substantial debt ($10.0 million principal as of September 30, 2025), which could impair flexibility and access to capital.
• The company is dependent on a single product candidate, cytisinicline, and its commercialization is dependent on securing sufficient quantities from limited natural sources or commercially viable synthetic routes.

Risks

• Substantial doubt exists as to the ability to continue as a going concern, dependent on raising additional capital.
• Failure to obtain additional financing when needed may prevent completion of development, regulatory approval, and commercialization of cytisinicline.
• Incurred substantial debt ($10.0 million principal as of September 30, 2025), which could impair flexibility and access to capital and adversely affect financial position if unable to service debt obligations.
• Cytisinicline is currently the sole product candidate, and there is no guarantee of successful FDA or other regulatory approval.
• Development and commercialization depend on securing sufficient quantities of cytisinicline from limited natural sources outside the United States, with no guarantee of commercially viable synthetic routes.
• Reliance on third parties to manufacture cytisinicline; commercialization could be stopped, delayed, or made less profitable if the dispute with Sopharma is not resolved, or if Sopharma fails FDA approval, supply, quality, or pricing.
• The FDA may not grant marketing approval without additional clinical or nonclinical studies, or at all.
• Failure to obtain necessary regulatory approvals in the United States and/or other countries will prevent sales of cytisinicline.
• Cytisinicline may cause undesirable side effects or have other properties that could delay or prevent regulatory approval, limit commercial viability, or result in negative consequences post-approval.
• Difficulty in evaluating current business, predicting prospects, and forecasting financial performance and growth.
• Substantial competition from major pharmaceutical companies, specialty pharmaceutical companies, biotechnology companies, universities, and other research institutions.
• Business may be negatively affected by weather conditions, natural disasters, and availability of natural resources, as well as climate change.
• Risk of using financial and human resources on less profitable programs, failing to capitalize on more profitable opportunities.
• The ongoing shutdown of the U.S. government may delay review or approval of the NDA.
• Receipt of a Complete Response Letter (CRL) from the FDA could result in reputational harm, litigation, or delays.
• Results of earlier clinical trials are not necessarily predictive of future results.
• Clinical trials are costly, time-consuming, and inherently risky, with potential for failure to demonstrate safety and efficacy.
• Discovery of contaminants or impurities (e.g., nitrosamines) above regulatory thresholds could delay development/approval or have a material adverse impact.
• Risk of product liability claims if cytisinicline harms patients or is perceived to cause harm to patients.
• Healthcare legislative and executive reform measures (e.g., Inflation Reduction Act) may adversely affect the business, financial condition, or results of operations.
• Potential reductions in federal spending in the U.S. and globally could impact ability to obtain services, reimbursement, or funding.
• Subject to ongoing regulatory requirements post-approval, with failure to comply leading to penalties or withdrawal of approvals.
• Subject to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws, with potential for substantial penalties for non-compliance.
• Risk of misconduct by employees, independent contractors, consultants, commercial partners, principal investigators, or CROs.
• Breakthrough Therapy designation and CNPV do not guarantee faster development, review, or approval, nor do they increase the likelihood of marketing approval.
• Difficulty in attracting, retaining, and motivating qualified personnel.
• Difficulties in managing organizational expansion for commercialization, potentially diverting attention and resources.
• Unsuccessful development of additional indications for cytisinicline (e.g., e-cigarette cessation) could adversely affect the business.
• Internal computer systems or those of third parties may fail or suffer security breaches and cyber-attacks, disrupting development programs.
• Potential risks associated with the integration and use of Artificial Intelligence (AI) by the company or third parties.
• Inability to establish distribution, marketing, and sales capabilities could hinder commercialization.
• The commercial success of cytisinicline will depend upon the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community.
• Sopharma may breach its supply agreement and sell cytisinicline into the company's territories, negatively affecting commercialization.
• Illegal distribution and sale of counterfeit versions of cytisinicline, stolen products, or alternative third-party distribution could harm financial performance or reputation.
• Inability to form collaborations could alter development and commercialization plans.
• Failure to identify, license, discover, develop, or commercialize additional product candidates.
• Subject to U.S. and foreign export/import controls, sanctions, embargoes, anti-corruption, and anti-money laundering laws.
• Inability to maintain effective proprietary rights (trade secrets, patents) could impair competitive position.
• Third-party claims of intellectual property infringement.
• Changes in patent law could diminish the value of patents.
• Risk of lawsuits to protect or enforce patents.
• Inability to protect intellectual property rights throughout the world.
• The price for our common stock is volatile.
• A significant portion of total outstanding shares of common stock may be sold into the public market at any point, which could cause the market price of common stock to drop significantly, even if the business is doing well, and result in significant dilution to stockholders.
• Smaller reporting company status may make common stock less attractive to investors.
• Risk of securities class action litigation.
• Incur costs and demands upon management as a result of complying with the laws and regulations affecting public companies.
• Shareholder activists could cause a disruption to the business.
• Anti-takeover provisions under Delaware law could make an acquisition of the company more difficult and may prevent attempts by stockholders to replace or remove management.
• Bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between the company and its stockholders, which could limit stockholders' ability to obtain a favorable judicial forum.
• Failure to maintain effective internal control over financial reporting could have a material adverse effect on reputation, results of operations and financial condition.
• Pre-merger net operating loss carryforwards and certain other tax attributes are subject to limitations due to an ownership change under Section 382 of the U.S. Internal Revenue Code.
• U.S. federal tax reform and changes in other tax laws could increase the tax burden and adversely affect the business and financial condition.

Future Outlook

The company expects to commence commercial sales of cytisinicline in the United States in the second half of 2026, if approved by the FDA. They anticipate substantial increases in expenses and operating losses as they continue commercialization and clinical development activities. The company will require substantial additional capital to fund operations and finance remaining development and commercialization efforts, with existing cash, cash equivalents, and marketable securities expected to fund operations into the second half of 2026. They may explore additional indications for nicotine dependence in the future.

Management Comments

• "We believe cytisinicline represents a unique opportunity to significantly impact global health by addressing the considerable unmet need among millions of smokers and e-cigarettes users."
• "If approved by the FDA, it may become one of the first new prescription medicines in nearly two decades aimed at aiding individuals in overcoming nicotine dependence."
• "We believe cytisinicline is differentiated from existing smoking cessation treatments given its combination of efficacy, well-tolerated safety profile, and a potential option for a shorter therapy duration as compared to existing prescription smoking cessation therapies, as demonstrated in clinical trials."
• "We plan to commence commercial sales of cytisinicline in the United States in the second half of 2026."
• "We believe we will be able to commercialize independently in the U.S. market by focusing our marketing and sales efforts on highly targeted prescriber and patient audiences."
• "We are planning to launch by utilizing a well-established marketing technology infrastructure and embedding AI tools to enhance targeting, decision making, and performance metrics."
• "Substantial doubt exists as to our ability to continue as a going concern. Our ability to continue as a going concern is subject to material uncertainty and dependent on our ability to obtain additional financing."

Industry Context

The company operates in the highly competitive pharmaceutical industry, specifically targeting nicotine dependence, a global epidemic responsible for over eight million deaths worldwide annually. Cytisinicline aims to address a significant unmet medical need, particularly for e-cigarette cessation where no FDA-approved therapies exist. The industry faces increasing scrutiny over drug pricing and potential legislative reforms (e.g., Inflation Reduction Act), as well as supply chain disruptions and geopolitical risks. The company's strategy to leverage AI tools for marketing aligns with broader industry trends in digital transformation and targeted commercialization.

Comparison to Industry Standards

• Cytisinicline is positioned as potentially one of the first new prescription medicines for nicotine dependence in nearly two decades, suggesting a gap in recent innovation from competitors.
• The company believes cytisinicline is differentiated from existing smoking cessation treatments (e.g., Pfizer's Chantix, which was recalled) due to its combination of efficacy, well-tolerated safety profile, and potential for shorter therapy duration.
• The FDA's Breakthrough Therapy designation and Commissioners National Priority Voucher for vaping cessation highlight cytisinicline's potential to offer substantial improvement over available therapies, as there are currently no FDA-approved therapies specifically for e-cigarette cessation.

Legal Proceedings

• Sopharma has alleged that the company's engagement of third-party manufacturers is a breach of their agreement, which the company has disputed and proposed steps to resolve. This dispute may result in litigation.
• The company is exposed to the risk of potential product liability claims if cytisinicline causes or is perceived to cause harm to patients.
• Potential for lawsuits against the FDA challenging its decisions and policies due to the U.S. Supreme Court's reversal of the Chevron doctrine.
• Risk of securities class action litigation following a decline in stock price.

Related Party Transactions

• Entered into two development agreements (Adare Agreements) with Adare Pharma Solutions on September 25, 2025. Thomas Sellig, the CEO of Adare, is also a member of the company's Board of Directors, chairs the Compensation Committee, and is a member of the Audit Committee.
• Expected to incur approximately $2.0 million in expenses over the term of the Adare Agreements.

Stakeholder Impact

• Shareholders: Significant dilution risk from future capital raises, potential stock price volatility, and the "going concern" warning. Potential for long-term value creation if cytisinicline is successfully commercialized.
• Employees: Potential for increased hiring for commercialization, but also uncertainty due to financial condition and need for additional capital. Stock-based compensation is a significant part of employee expense.
• Customers (Future Patients): Potential for a new, differentiated treatment option for smoking and vaping cessation if cytisinicline is approved.
• Suppliers/Manufacturers: Ongoing dispute with Sopharma could impact supply chain stability. Reliance on third-party manufacturers introduces risks.
• Creditors (SVB/FCB): Secured debt obligations, with potential for foreclosure on assets if unable to make payments. Conversion rights for debt holders into common stock.

Next Steps

• FDA review of NDA for smoking cessation with PDUFA target action date of June 20, 2026.
• Launch planning and readiness activities for commercial sales of cytisinicline in the U.S. in the second half of 2026, if approved.
• Initiate a single Phase 3 study for vaping cessation, targeting enrollment and completion of study evaluations approximately 12 months after initiation.
• Continue efforts to resolve the dispute with Sopharma regarding third-party manufacturers.
• Require substantial additional capital from various sources to fund operations and finance remaining development and commercialization.
• Potential draw down of a third $5.0 million tranche from the New Convertible Term Loan by December 31, 2025.
• Explore additional indications for the treatment of nicotine dependence in the future.

Key Dates

Recommendation

The company has achieved significant regulatory milestones with FDA acceptance of its NDA for smoking cessation and Breakthrough Therapy/CNPV for vaping cessation, which are strong positive indicators for future commercial potential. However, these positives are overshadowed by a substantial increase in net loss and cash burn, an explicit "going concern" warning, and the immediate need for significant additional capital. The dispute with Sopharma adds further uncertainty to the supply chain. While the long-term prospects for cytisinicline are promising, the near-term financial instability and reliance on future financing make it a high-risk investment. A "hold" recommendation reflects the balance between the strong clinical progress and the severe financial challenges, suggesting investors monitor closely for successful capital raises and resolution of the Sopharma dispute before making further investment decisions.

Keywords

Cytisinicline, Smoking Cessation, Vaping Cessation, FDA NDA, Breakthrough Therapy, Commissioners National Priority Voucher, ORCA-OL Trial, Pharmaceutical Development, Clinical Trials, Nicotine Dependence, Biotechnology, SEC Filing, 10-Q, Achieve Life Sciences, Sopharma Dispute, Capital Raise, Going Concern, Drug Approval, Commercialization